Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Feb 9, 2026
Reporting period
Not applicable
Filed with the SEC
Feb 12, 2026
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001140361-26-004890
Filed / recorded
Feb 12, 2026, 2:00 AM UTC
Added to OQRO
Oct 6, 2026, 9:54 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
ADMA BIOLOGICS, INC.
Issuer CIK
1368514
Ticker
ADMA
Reporting person
Adam S Grossman
Relationship
Director, Officer
Officer title
President and CEO
Security
Stock Option (right to buy)
Table
Derivative (Table II)
Transaction date
Feb 9, 2026
Transaction code
A
Shares / units
444,711
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
444,711
Ownership form
Direct
Amendment
No
Footnotes from the filing
The options vest over four years with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 9, 2030 in accordance with the Plan.